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There is an increasing interest in targeting molecules to the mitochondrial
matrix. Many proteins are naturally imported through the translocase com-
plexes found in the outer and inner mitochondrial membranes. One possible
means for importing molecules is therefore to use a mitochondrial pre-
protein as a vector and assess what forms of molecules can be attached to
the pre-protein as cargo. A major difficulty with this approach is to ensure
that any chimaeric molecule does indeed access the mitochondrial matrix
and does not merely associate with the mitochondrial membranes. We
have recently demonstrated that click chemistry can be used both to demon-
strate convincingly mitochondrial import of a peptide–peptide nucleic acid
conjugate and also to quantify the mitochondrial uptake for specific syn-
thetic conjugates. We now report an adaptation of the synthesis to
facilitate simple quantification of multiple molecules and hence to calculate
the efficiency of their mitochondrial import.1. Introduction
Human mitochondrial DNA (mtDNA) is found in large copy number in nearly
all nucleated cells. In mammals, this small (16 569 bp) genome encodes just
13 polypeptides and all the RNA components (2 mt-rRNAs and 22 mt-
tRNAs) required for their intra-mitochondrial synthesis. All 13 proteins are
members of four of the five multi-subunit complexes of the mitochondrial
inner membrane that couple oxidative phosphorylation (OXPHOS). Mutations
in the mitochondrial genome can cause a wide variety of progressive disorders
mostly affecting the muscle or nervous system [1] and often the patient will pre-
sent with two subpopulations of mtDNA, one wild-type and one mutated, a
situation termed heteroplasmy [2]. Mutations would be predicted to affect
the levels of normal mtDNA-encoded proteins, either directly by resulting in
the loss or mutation of protein-coding genes, or by a similar loss or mutation
of mt-RNA affecting the synthesis of these proteins. Thus, mutations would
be predicted to cause a defect in the maintenance of the OXPHOS machinery.
Pathogenesis, however, is complicated by heteroplasmy. As mutations are
nearly always recessive, cells can tolerate the presence of a level of mutated
mtDNA without any loss of OXPHOS activity. Indeed, OXPHOS dysfunction
only becomes apparent when mutation loads rise above a certain threshold
level, a level that is reported to vary dependent on the pathogenic mtDNA
mutation and the cell type [3]. To date, there is no effective treatment for the
vast majority of patients with mtDNA disease.
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to try and manipulate the level of heteroplasmy as a potential
therapeutic intervention [4]. We reasoned that if it were poss-
ible to selectively target the mutated mtDNA and prevent it
from replicating, the wild-type would propagate over time,
potentially restoring OXPHOS and slowing progression of
the disorder. This antigenomic approach to treating patients
with mtDNA disease requires the design of an antigenomic
agent that can target mitochondria in whole cells and be
imported into the mitochondrial matrix where the mtDNA
resides. To facilitate selective binding to the mutated mol-
ecule, nucleobase derivatives such as peptide nucleic acids
(PNAs) were used [5]. Novel synthetic derivatives were tar-
geted to mitochondria as a function of their charge, and
were predicted to promote the direct transfer of chimaeric
molecules across membranes. Unfortunately, although
many candidates have been synthesized, and several
methods have demonstrated a clear co-localization of the
antigenomic molecules to mitochondria in whole cells, resol-
ution of these techniques has never been sufficient to
convincingly show that the molecules have accessed the mito-
chondrial matrix [6]. A second approach was to add a
synthetic mitochondrial pre-protein to the derivatives, to
exploit the natural protein import machinery of the mitochon-
drion. The mitochondrial processing peptidase (MPP) would
be predicted to cleave the mitochondria targeting sequence
(MTS) of imported proteins, and thus, by extension,
peptide–PNA conjugates [7]. While cleavage of the MTS by
MPP is often regarded as evidence of protein uptake into iso-
lated mitochondria, it has been shown that cleavage of the
MTS can also occur to some extent while the cargo is still
located bound to the translocase at the inner membrane,
resulting in erroneous interpretation of the results [8].
Recently, we have used the ClickIn strategy to show
unequivocally that a mitochondrial pre-protein carrying a
short peptide nucleic acid as cargo could be imported
through the natural mitochondrial protein import machinery
[9]. To do this, we used the mitochondrial membrane poten-
tial to concentrate the mitochondrially targeted cyclooctyne,
MitoOct [10] and measured the formation of the intact clicked
conjugate on import of a peptide–PNA–azide (figure 1).
With the appropriate negative controls, this technique can
easily confirm the localization of compounds in the mito-
chondrial matrix. In this report, we present a modified
ClickIn strategy, where we make use of both the ClickIn reac-
tion in energized mitochondria and the removal of the MTS
by MPP. The combination of both strategies allows both
qualitative and quantitative observation of mitochondrial
uptake. Furthermore, we report an optimized method for
the synthesis of the required peptide–PNA conjugates. The
synthesis of such large molecules (more than 30 residues) in
a linear manner can be challenging, with side products result-
ing from incomplete steps in the synthesis as well as the final
cleavage and deprotection step contaminating the product.
To resolve this issue, a simple strategy for ligation of indepen-
dently synthesized peptide and PNA moieties has been
designed. The conjugation of peptides and PNAs using
cysteine alkylation has been previously described and is
well established in the field [11,12]. Traditionally, this reac-
tion has proved to be highly reliable, with few side
products caused by alkylation of other nucleophilic residues
(e.g. amines or imidazoles). In addition, the reaction is carried
out under very mild conditions at neutral to slightly basic pH(7.5–8) in an aqueous buffer, avoiding the possibility of epi-
merization of the amino acids in the peptide.2. Experimental procedure
2.1. Materials
Fmoc-PNA monomers were obtained from Link Technologies
(UK). N-alpha-t-butyloxycarbonyl-L-glutamic amide (Boc-L-
Glu-NH2) was obtained from Iris Biotech (Germany). Fmoc
protected amino acids were obtained from AGTC Biopro-
ducts (UK). All other reagents and chemicals were obtained
from Sigma-Aldrich. Mass spectrometry was performed on
an Applied Biosystems Voyager-DE PRO MALDI-TOF spec-
trometer in linear mode, and processed using mMass.
HPLC purification was performed on a Varian 940-LC
equipped with a Phenomenex Luna C18 column (250 
10 mm, 10 mm) using a flow rate of 4 ml min21. For the chro-
matograms in figure 2 a gradient of 0–75% B in 25 min was
used (A is 0.1% TFA in H2O, B is 0.1% in acetonitrile).
HPLC chromatograms of purified compounds are provided
in the electronic supplementary material.2.2. Peptide synthesis and deprotection
Peptides and PNAs were synthesized on a Liberty Blue pep-
tide synthesizer using microwave irradiation on a Rink amide
ChemMatrix support using Fmoc chemistry with five equiva-
lents of Fmoc-amino acids, N,N0-diisopropyl-carbodiimide
(DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma) in a
1 : 1 : 1 ratio in dimethylformamide (DMF) unless otherwise
specified.
After synthesis, the resin was washed with DMF (3),
dichloromethane (3) and diethyl ether (3) and dried in
vacuo for a minimum of 3 h. The peptides and PNAs were
cleaved off the resin and deprotected by addition of an
acidic cleavage cocktail for 60–90 min. Then, the solution
was filtered off the resin, followed by washing of the resin
(3  2 ml). The solution was evaporated using nitrogen
flow, reducing the volume to 2 ml, after which 10 ml of
cold diethyl ether was added, precipitating the peptide. The
suspension was centrifuged and the supernatant was dec-
anted. The pellet was resuspended in 10 ml of cold diethyl
ether, followed by centrifugation, the ether was removed by
decantation and the pellet dried in vacuo. The dried peptide
was redissolved in 1 ml of Milli-Q water and purified on
HPLC, where fractions with purity more than 95% (by MS)
were selected.2.3. COX8-Cys-NH2 (1)
The peptide was synthesized on a 50 mmol scale. Fmoc-
Cys(Trt)-OH and Fmoc-His(Trt)-OH were coupled at 508C,
other amino acids were coupled at 758C for 10 min. Fmoc-
Arg(Pbf)-OH was coupled using double couplings, as well
as residues 1 to 12 (N-terminus). In total, 10 mmol of the pep-
tide was deprotected and cleaved off the resin using 5 ml of
TFA/DODT/TIS/H2O (94 : 2,5 : 1 : 2,5) for 90 min. Purifi-
cation of the peptide on HPLC was carried out using a 0–
100% gradient (3 min 100% A, then to 100% B in 22 min,
with the peptide eluting at 65%B): m/z 3255.64 observed
(3254.91 calculated).
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Figure 1. (a) The ClickIn strategy makes use of a slow but bioorthogonal reaction between MitoOct and an azide-labelled peptide–PNA conjugate 6. Upon click
reaction and import, the MTS is cleaved from the clicked conjugate 7 presumably by the MPP and the resulting product 8 is quantified using MALDI-TOF MS as
described. (b) Structures of the clicked conjugate 7 and its MPP processed form 8. (c) To quantify the formed clicked PNA 8, a suitable internal standard 5 was
synthesized using isoglutamine to replace the Cys(Ac)-NH2. All syntheses are described in the Experimental procedure section. (Online version in colour.)
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In total, 25 mmol resin was allowed to swell in DMF for
10 min, after which 75 mmol Fmoc-azido-lysine (Fmoc-
Lys(N3)-OH), 75 mmol benzotriazole-1-yl-oxy-tris-pyrroli-
dino-phosphonium hexafluorophosphate and 150 mmolN,N-diisopropylethylamine dissolved in DMF was added to
the resin. The resinwas shaken for 90 min, afterwhich the reac-
tion mixture was filtered and the resin was washed with DMF
(6  2 ml). The resin was loaded into the Peptide Synthesizer
and the PNAwas synthesized byautomatedpeptide synthesis.
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Figure 2. (a) Scheme showing the reaction between cysteine modified COX8 peptide 1 and bromo-acetylated PNA 3. (b) Overlay of chromatograms of 1, 3, and the
crude reaction mixture containing 6 after 1 h at 378C are shown. All syntheses are described in the Experimental procedure section. (Online version in colour.)
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(5% acetic anhydride, 6% 2,6-lutidine in DMF) for 5 min at
room temperature. Fmoc-deprotection was carried out in two
treatments with 20% piperidine in DMF for 1 and 3 min at
room temperature. The resin, now with the completed
sequence, was washed with DMF, DCM and diethyl ether
(3 each) and dried in vacuo.
2.5. Bromo-Ac-GTCA-Lys-(N3)-NH2 (3)
In total, 20 mmol 2 was left to swell in DMF for 30 min. In a
separate tube, 200 mmol DIC was mixed with 200 mmol
bromoacetic acid in 400 ml DMF and left to activate the
bromoacetic acid for 30 min, after which it was added to the
resin [13]. The activated mixture was then added to the
resin, and left to react for 90 min. The PNAwas subsequently
deprotected as described (see above) using TFA/TIS/H2O (95
: 2,5 : 2,5) and purified by HPLC on a 0–75% gradient (0 to75% B in 25 min, with the compound eluting at 42% B): m/z
1376.10 observed (1375.47 calculated).
2.6. isoGln-GTCA-Lys-(N3)-NH2 (4)
In total, 5 mmol 2 was left to swell in DMF for 30 min. In a
separate tube, 50 mmol DIC, HOAt and Boc-L-Glu-NH2
were mixed in 250 ml DMF and added without pre-activation
to the resin and left to react for 90 min. The PNA was sub-
sequently deprotected as described [3] using TFA/TIS/H2O
(95 : 2,5 : 2,5) and purified by HPLC on a 0–75% gradient
(0–75% B in 25 min, with the desired compound eluting at
38% B). m/z 1383.53 observed (1383.60 calculated).
2.7. isoGln-GTCA-Lys-(click)-NH2 (5)
To 50 nmol 4 was added 60 nmol MitoOct in MeOH, and the
mixture was evaporated in a SpeedVac. The residue was
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repeated for five times, until completion of the reaction. The
obtained product was purified byHPLC using a 0–75% gradi-
ent (0–75% B in 25 min, with the desired compound eluting at
50% B). m/z 1853.25 observed (1853.83 calculated).
2.8. COX8-Cys-Ac-GTCA-Lys(N3)-NH2 (6)
To 50 nmol 3 was added 100 nmol 1 in 60 ml 20 mM
ammonium bicarbonate buffer (pH 7.5) and left to react for
1 h at 378C. The reaction was stopped by addition of 450 ml
0.1% TFA in H2O and the product was purified by HPLC
using a 0–75% gradient (0–75% B in 25 min, with the desired
compound eluting at 53% B), which was then lyophilized and
dissolved in 50 ml of millipure water. m/z 4550.33 observed
(4550.45 calculated).
2.9. Uptake experiments in isolated rat liver
mitochondria
Rat liver mitochondria were prepared by differential centrifu-
gation as previously described [14], and diluted to a
20 mg protein ml21 concentration in STE buffer (250 mM
sucrose, 5 mM Tris, 1 mM EGTA, pH 7.4) and stored for a
maximum of 3 h on ice. Peptide–PNA 6 was dissolved at
the indicated concentrations in 100 ml KCl buffer (120 mM
KCl, 10 mM HEPES, 1 mM EGTA, 1 mM ADP, 1 mM
MgCl2, 1 mM KPi, 0.05% BSA, pH 7.4) supplemented with
10 mM potassium succinate, 4 mg ml21 rotenone and 10 mM
MitoOct. Where indicated carbonyl cyanide-4-(trifluoro-
methoxy)phenylhydrazone (FCCP, 500 nM) was added to
the buffer. The buffer was warmed for 5 min at 378C after
which the reaction was initiated by addition of 5 ml mito-
chondria suspension (100 mg protein). The mitochondria
were incubated for 1 h at 378C, after which the reaction was
stopped by the addition of 3-phenyl-1,2,4,5-tetrazine (PhTet,
50 mM). The mitochondria were pelleted by centrifugation
at 16 000g for 1 min, and supernatant was removed. Next
100 ml 20% acetonitrile solution with 0.1% formic acid,
50 mM PhTet and 0.1 mM internal standard 5 was added to
the pellet. The pellet was suspended by three cycles of freez-
ing in solid CO2 (5 min) and sonication in a Grant
XB2 ultrasonic bath. The obtained solution was centrifuged
at 16 000g for 10 min. The sample was spotted onto an
MALDI-plate using the bottom-layer method. Matrix
(0.75 ml, 50% acetonitrile, 5 mg ml21 a-cyano-4-hydroxycin-
namic acid, 10 mM dibasic ammonium citrate, 0.1% TFA)
was spotted on the plate and 0.75 ml sample was mixed in.
The spot was left to dry at room temperature, after which
another layer of 0.75 ml of matrix was added. In total, 20 spec-
tra with 10 shots each were collected per spot, using a
minimum intensity of 1000 and a maximum of 10 000 as
selection criterion, averages were taken of three spots per
experiment. All experiments were performed in triplicate
using different mitochondrial preparations and are presented
as averages +s.e.m.3. Results and discussion
3.1. Peptide–PNA conjugation
Previously, we have shown that click chemistry can be used
to measure import of a peptide–PNA conjugate into the
matrix of isolated mitochondria [9]. When carrying outthese experiments, it was uncertain what, if any, type of con-
jugation between the MTS and the PNA would be tolerated
by the translocases of the outer and inner mitochondrial
membranes. We therefore chose to synthesize our targeted
PNA in a linear manner on solid phase, in which the conju-
gate thus only consisted of amide bonds. While the
synthesis of these conjugates was robust, it was time consum-
ing and required a new complete and continuous synthesis
for every conjugate that was to be tested, hampering the
optimization of molecules for import. We therefore wished
to examine an alternative method, which would allow for
the rapid addition of an efficient peptide pre-sequence to a
separately synthesized PNA by simple ligation. Addition of
excess COX8-Cys-NH2 (1) to the bromo-acetylated PNA
azide (3) in a 20 mM ammonium bicarbonate buffer rapidly
drove the reaction to completion (figure 2). The product
appeared as a single sharp peak in the chromatogram, separ-
ated from both peptide and PNA starting materials, allowing
simple isolation of the product in good yield (80%). This pro-
cedure not only facilitates the efficient synthesis of large
peptide–PNA constructs in high purity, it also allows rapid
generation of libraries, and the comparison of different com-
binations of peptide (cell penetrating peptides, mitochondria
targeting sequences, combinations thereof) and PNA (differ-
ent lengths, sequences, linkers) or other types of cargo.
3.2. Quantification of in organello imported and cleaved
peptide–PNA conjugate
Following the successful synthesis and purification of our
peptide–PNA conjugate constructs, we wished to determine
whether these molecules were imported into mitochondria,
as judged both by membrane potential-dependent cleavage
of the pre-sequence and formation of clicked products.
Isolated rat liver mitochondria were incubated with var-
ious concentrations of peptide (0.1–10 mM) in import
buffer, in the presence of MitoOct, for 1 h at 378C. As pre-
viously described, the reaction was stopped by addition of
PhTET and centrifugation. The pellet was extracted (20%
acetonitrile, 0.1% formic acid, 50 mM PhTet, 0.1mM 5) and
analysed by MALDI-TOF (figure 3 and electronic supplemen-
tary material, S1). The mass spectra indicate that the MTS was
indeed removed from the clicked PNA, indicating that both
MitoOct and the MPP are involved in the conversion of the
peptide–PNA conjugate 6 into 8 (figure 1). Significant
amounts of clicked PNA were observed in all samples com-
pared to the FCCP control. Moreover, when FCCP was
added to uncouple the mitochondrial membrane potential,
no product 8 could be observed at any of the added
peptide–PNA concentrations. This is consistent with FCCP
not only inhibiting the ClickIn reaction, but also inhibiting
the processing of COX8-PNA-click [7] by stopping import
of 6. The absence of signal in the presence of FCCP is striking
(figure 3 and electronic supplementary material, S1), and
enables the qualitative observation of PNA uptake in
isolated mitochondria. Finally, the quantitative analysis of
the reaction shows a typical dose–response curve for concen-
trations of 6 up to 5 mM (figure 3c), and indicates higher
concentrations of 6might have a toxic effect on the mitochon-
dria, as previously observed [9]. It is interesting to note that,
even though the MPP is known to cleave after the 25th resi-
due of the COX8 pre-sequence [15], we see no evidence of
the four amino acids, IHSL, predicted to remain at the
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lished results have shown a very minor amount of the PNA
product still carrying leucine at the N-terminal but not
any of the remaining amino acids. It is likely that these
residues are removed by a protease residing in the
mitochondrial matrix.
In summary, we report the optimization of a synthesis
protocol that should allow for the ligation of a peptide pre-
sequence with a library of diverse PNA or other nucleobase
cargoes and confirm that our methods can reliably quantify
the matrix import of cleaved molecules in organello. We
now intend to tailor these methods to investigate the possi-
bility of mitochondrial import of such antigenomic
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